Drug Name: 

DUPILUMAB*

Drug Description: 
IL-4R Antibody
Target Condition: 
Atopic dermatitis in children, eosinophilic esophagitis
Rank: 
10
Phase: 
Phase 2

NOW APPROVED IN THE UNITED STATES